New French agency head to prioritize drug/device safety, access to innovation
This article was originally published in Clinica
Executive Summary
Dominique Martin, the new director general of the French medicines and health products safety agency, ANSM, says he plans to focus on strengthening post-marketing safety monitoring of medicines, facilitating access to therapeutic innovation, and beefing up France's regulatory influence at the European level.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.